Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer

Draft scope assessment: unclear. Attached because the study's own record describes recurrent disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Defined by the detection of at least 50% donor derived T-cells (CD3+), as a proportion of the total T-cell population

Patients receiving haploidentical transplant who had T cell chimerism tested at day +84

→

primary · POSTED

Grade III GVHD represents moderate severity. Grade IV GVHD represents extreme severity

Source null

→

primary · POSTED

Number of deaths without progression or recurrence of malignant disease

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
nct id: NCT00049504
trial label: Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
applicability: unclear
applicability note: Attached because the study's own record describes recurrent disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 3
harms Count: 1
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
nct id
NCT00049504
outcome key
om-0000
source section id
NCT00049504-om-0000
source outcome index
0
endpoint
Donor Engraftment (Chimerism)
endpoint definition
Defined by the detection of at least 50% donor derived T-cells (CD3+), as a proportion of the total T-cell population
time origin
At day +84 after transplantation
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Patients receiving haploidentical transplant who had T cell chimerism tested at day +84
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
nct id
NCT00049504
outcome key
om-0001
source section id
NCT00049504-om-0001
source outcome index
1
endpoint
Incidence of Grades III-IV Acute GVHD
endpoint definition
Grade III GVHD represents moderate severity. Grade IV GVHD represents extreme severity
time origin
At any time within 200 days after transplantation
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
nct id
NCT00049504
outcome key
om-0002
source section id
NCT00049504-om-0002
source outcome index
2
endpoint
Non-relapse-related Mortality
endpoint definition
Number of deaths without progression or recurrence of malignant disease
time origin
Up to 200 days after transplantation
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
nct id
NCT00049504
outcome key
om-0000
arm key
OG000
arm label
Treatment (Nonmyeloablative HSCT)
regimen
NONMYELOABLATIVE CONDITIONING: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1 hour on days -6 and -5. Patients undergo total body irradiation on day -1. TRANSPLANTATION: Patients undergo BMT, from an HLA-haploidentical donor, on day 0. POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on day 3. GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV over 1-2 hours and then tacrolimus PO, once tolerated, on days 4-180, with taper on day 86 in the absence of graft-versus-host disease. Patients also receive mycophenolate mofetil PO three times daily on days 4-35.
analyzed count
36
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00049504-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
nct id
NCT00049504
outcome key
om-0001
arm key
OG000
arm label
Treatment (Nonmyeloablative HSCT)
regimen
NONMYELOABLATIVE CONDITIONING: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1 hour on days -6 and -5. Patients undergo total body irradiation on day -1. TRANSPLANTATION: Patients undergo BMT, from an HLA-haploidentical donor, on day 0. POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on day 3. GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV over 1-2 hours and then tacrolimus PO, once tolerated, on days 4-180, with taper on day 86 in the absence of graft-versus-host disease. Patients also receive mycophenolate mofetil PO three times daily on days 4-35.
analyzed count
55
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00049504-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
nct id
NCT00049504
outcome key
om-0002
arm key
OG000
arm label
Treatment (Nonmyeloablative HSCT)
regimen
NONMYELOABLATIVE CONDITIONING: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1 hour on days -6 and -5. Patients undergo total body irradiation on day -1. TRANSPLANTATION: Patients undergo BMT, from an HLA-haploidentical donor, on day 0. POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on day 3. GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV over 1-2 hours and then tacrolimus PO, once tolerated, on days 4-180, with taper on day 86 in the absence of graft-versus-host disease. Patients also receive mycophenolate mofetil PO three times daily on days 4-35.
analyzed count
55
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00049504-om-0002#groups/OG000

harms

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
nct id
NCT00049504
harm key
EG000
source section id
NCT00049504-ae
event group key
EG000
event group label
Treatment (Nonmyeloablative HSCT)
serious affected
11
serious at risk
55
other affected
55
other at risk
55
frequency threshold
0
collection period
Source null
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice